Castration-resistant prostate cancer is frequently driven by sustained androgen receptor activity, including through constitutively active androgen receptor splice variants such as androgen receptor variant 7, which lack the ligand-binding domain and evade classical androgen receptor–targeted therapies.4 This evidence concerns the gene AR and prostate carcinoma.